Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Cambridge, Mass. – September 13, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.

Los Angeles – September 13, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.

Toronto – September 13, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Ramat Gan, Israel – September 13, 2026 -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) will rebrand as Eocene Ltd. and begin trading under the ticker EOCN on the Nasdaq Capital Market starting September 10, 2026, after terminating its $20 million standby equity purchase agreement with Yorkville and regaining compliance with Nasdaq's minimum bid price rule.

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

Dallas – September 13, 2026 -- The U.S. Food and Drug Administration has accepted and filed the Biologics License Application for MOGENRY, an optogenetic gene therapy from Nanoscope Therapeutics designed to restore vision in retinitis pigmentosa patients with severe vision loss. If approved, MOGENRY would become the first gene-agnostic treatment available for this patient population, which currently has no approved therapy.